EGFR-Multiplex 0.1% AF cfDNA in Plasma: A Breakthrough for Liquid Biopsy Research and Diagnostics

EGFR-Multiplex 0.1% AF cfDNA in Plasma is a revolutionary tool designed for precision diagnostics and research. EGFR mutations are key driver mutations commonly associated with lung and breast cancers, making them critical targets for therapeutic research and clinical applications. This advanced product, developed by SensID, includes a selection of clinically relevant Epidermal Growth Factor Receptor (EGFR) mutations. It features both Tyrosine Kinase Inhibitor (TKI) sensitive and TKI-resistant mutations, addressing the growing need for reliable diagnostic standards in the treatment of Non-Small Cell Lung Cancer (NSCLC).

The EGFR-Multiplex 0.1% AF cfDNA in Plasma serves as an essential positive standard for liquid biopsy assays. Laboratories and R&D departments can rely on this product for the validation, development, and performance testing of EGFR diagnostic kits. Its meticulously engineered formulation is particularly suited for liquid biopsy applications, enhancing the accuracy and reliability of mutation detection in circulating cell-free DNA (cfDNA).

What sets EGFR-Multiplex 0.1% AF cfDNA in Plasma apart is its background material. Derived from human cfDNA of the Ashkenazim Son cell line and embedded within human-tech recreated plasma, this product ensures a high-fidelity simulation of real clinical samples. Such realistic conditions are crucial for researchers developing and validating liquid biopsy technologies, as they help minimize false positives and negatives, ultimately improving patient outcomes in clinical settings.

The significance of EGFR mutations lies in their role as both prognostic and predictive biomarkers. EGFR mutations can dictate how a patient responds to TKI therapies, making accurate mutation detection imperative. By using EGFR-Multiplex 0.1% AF cfDNA in Plasma, researchers and clinicians can ensure the robustness and accuracy of their assays. This product empowers laboratories to differentiate between TKI-sensitive and TKI-resistant mutations, guiding personalized treatment strategies for patients with NSCLC.

In clinical research, detecting EGFR mutations at low allele frequencies is particularly challenging. The EGFR-Multiplex 0.1% AF cfDNA in Plasma addresses this challenge by providing a reliable, low allele frequency standard that mimics the genetic complexity of real patient samples. This product’s 0.1% allele frequency cfDNA is designed to support rigorous assay development, enabling accurate detection even at minimal mutation levels, which is vital for early-stage cancer diagnostics and monitoring.

EGFR-Multiplex 0.1% AF cfDNA in Plasma is indispensable for developing next-generation sequencing (NGS) techniques and polymerase chain reaction (PCR) assays. Laboratories seeking to standardize and validate their liquid biopsy assays will find this product an invaluable resource for achieving high sensitivity and specificity. Its application extends beyond diagnostics; researchers can use it for drug development, therapeutic monitoring, and biomarker discovery, thereby accelerating innovations in precision oncology.